Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF for prevention of clofarabine-induced neutropenia in pediatric Langerhans cell histiocytosis
ChiCTR2500114943Phase 4Not yet recruiting
- Sponsor
- West China Second University Hospital
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegfilgrastim in Langerhans cell histiocytosis (LCH), sponsored by West China Second University Hospital. Primary endpoint: Incidence of grade 3/4 neutropenia during each chemotherapy cycle. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on ChiCTR2500114943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114943.